Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808973 | 1.00 | CYP2C19 (0.69) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL6857308 | 0.87 | NPC1 (0.57) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL29437050 | 0.85 | POLB (0.72) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL110042 | 0.85 | POLB (0.72) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL27644581 | 0.85 | PDK1 (0.56) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL2943260 | 0.85 | PDK1 (0.56) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL2837597 | 0.85 | POLB (0.56) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL6970301 | 0.85 | CYP2C19 (0.67) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL27819891 | 0.85 | POLB (0.72) | CYP2C19POLBALDH1A1HPGDNPC1 | |
| SCHEMBL6689158 | 0.84 | ALDH1A1 (0.74) | CYP2C19POLBALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102516252-A | Preparation method of Nedocromil sodium | SICHUAN DIHON MEDICAL DEV CO LTD | 2012-06-27 | — | — | CN | claimed |
| US-6500935-B2 | REACTING SAID INTERMEDIATE WITH AN AMINE-CONTAINING COMPOUND TO FORM A DISAZO DYE | MILLIKEN & COMPANY | 2002-12-31 | — | — | US | claimed |
| US-20020107371-A1 | Aromatic bis-acetoacetamide intermediates | MILLIKEN & COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002044282-A2 | AROMATIC BIS-ACETOACETAMIDE INTERMEDIATES | MILLIKEN & COMPANY (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-114835687-A | AhR inhibitors | 重庆华森制药股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-2252293-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-9290480-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | Shin Poong Pharmaceuticals Co., Ltd. (KR) | 2016-03-22 | — | — | US | disclosed |
| CN-103124731-B | Fused heteroaryl compounds and uses thereof | HUTCHISON MEDIPHARMA LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| EP-1613600-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-4810282-A | 3-ORTHO-(ISOXAZOLYL,ISOTHIAZOLYL, PYRAZOLYL,THIADIAZOLYL, OXADIAZOLYL AND TRIAZOLYL BENZENESULFONUREYLENE-1,2,4-TRIAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0083975-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
| US-4695311-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-09-22 | — | — | US | disclosed |
| US-4606755-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4511392-A | N--/PYRIMIDIN-2-YLAMINOCARBENYL/-HETERO-SUBSTITUETED BENZENSESULFO | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-16 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | CYP2C19 4669/4885POLB 4812/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.